Scheme Pending

Eli Lilly and Company acquisition of Centessa Pharmaceuticals

US$6.3bn equity value

Announced 31 Mar 2026 · NASDAQ: CNTA · US$38.00 cash per share

Advisers

Centessa Pharmaceuticals

Target

Financial adviser
Legal adviser
Fairness opinion

Eli Lilly and Company

Acquirer

Financial adviser
Legal adviser
Target
Centessa Pharmaceuticals
Acquirer
Eli Lilly and Company
Target based in
United Kingdom
Buyer based in
United States
Structure
Scheme of arrangement
Sector
Biotech
Tags
Biotech, Pharma

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.